Arrowstreet Capital, Limited Partnership Eli Lilly & CO Transaction History

Arrowstreet Capital, Limited Partnership

$108 Billion
Q1 2024

A detailed history of Arrowstreet Capital, Limited Partnership transactions in Eli Lilly & CO stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 1,168,926 shares of LLY stock, worth $1.03 Billion. This represents 0.84% of its overall portfolio holdings.

Number of Shares

1,168,926

Previous 939,671 24.4%

Holding current value

$1.03 Billion

Previous $548 Million 66.02%

% of portfolio

0.84%

Previous 0.57%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$592.2 - $792.28 $136 Million - $182 Million	229,255 Added 24.4%	1,168,926 $909 Million
Q4 2023 Feb 14, 2024	SELL	$525.19 - $619.13 $279 Million - $329 Million	-531,981 Reduced 36.15%	939,671 $548 Million
Q3 2023 Nov 14, 2023	BUY	$434.7 - $599.3 $39.2 Million - $54 Million	90,169 Added 6.53%	1,471,652 $790 Million
Q2 2023 Aug 14, 2023	SELL	$350.74 - $468.98 $23 Million - $30.8 Million	-65,688 Reduced 4.54%	1,381,483 $648 Million
Q1 2023 May 15, 2023	SELL	$310.63 - $364.82 $151 Million - $177 Million	-486,045 Reduced 25.14%	1,447,171 $497 Million

Q4 2022 Feb 14, 2023	SELL	$321.55 - $374.67 $177 Million - $206 Million	-549,575 Reduced 22.14%	1,933,216 $707 Million
Q3 2022 Nov 14, 2022	SELL	$296.48 - $337.87 $322 Million - $367 Million	-1,086,020 Reduced 30.43%	2,482,791 $803 Million
Q2 2022 Aug 15, 2022	BUY	$278.73 - $327.27 $71.7 Million - $84.1 Million	257,098 Added 7.76%	3,568,811 $1.16 Billion
Q1 2022 May 13, 2022	BUY	$234.69 - $291.66 $275 Million - $342 Million	1,172,504 Added 54.81%	3,311,713 $948 Million
Q4 2021 Feb 14, 2022	BUY	$224.85 - $279.04 $244 Million - $303 Million	1,084,730 Added 102.87%	2,139,209 $591 Million
Q3 2021 Nov 12, 2021	BUY	$221.6 - $272.71 $219 Million - $270 Million	988,944 Added 1509.03%	1,054,479 $244 Million
Q2 2021 Aug 13, 2021	SELL	$180.55 - $233.54 $62.3 Million - $80.6 Million	-345,272 Reduced 84.05%	65,535 $15 Million
Q1 2021 May 14, 2021	SELL	$164.32 - $212.72 $70.9 Million - $91.8 Million	-431,735 Reduced 51.24%	410,807 $76.7 Million
Q4 2020 Feb 12, 2021	SELL	$130.46 - $172.63 $52.3 Million - $69.2 Million	-400,917 Reduced 32.24%	842,542 $142 Million
Q3 2020 Nov 12, 2020	BUY	$146.22 - $169.13 $50.2 Million - $58.1 Million	343,566 Added 38.18%	1,243,459 $184 Million
Q2 2020 Aug 12, 2020	BUY	$136.42 - $164.18 $91.9 Million - $111 Million	673,427 Added 297.36%	899,893 $148 Million
Q1 2020 May 15, 2020	BUY	$119.05 - $147.35 $13 Million - $16.1 Million	109,069 Added 92.91%	226,466 $31.4 Million
Q4 2019 Feb 13, 2020	SELL	$106.92 - $132.43 $115 Million - $142 Million	-1,074,974 Reduced 90.15%	117,397 $15.4 Million
Q3 2019 Nov 14, 2019	SELL	$106.79 - $116.16 $22.6 Million - $24.5 Million	-211,300 Reduced 15.05%	1,192,371 $133 Million
Q2 2019 Aug 14, 2019	BUY	$110.79 - $129.32 $86 Million - $100 Million	776,173 Added 123.69%	1,403,671 $156 Million
Q1 2019 May 15, 2019	SELL	$111.31 - $131.02 $182 Million - $214 Million	-1,636,116 Reduced 72.28%	627,498 $81.4 Million
Q4 2018 Feb 14, 2019	SELL	$105.9 - $118.64 $145 Million - $163 Million	-1,372,608 Reduced 37.75%	2,263,614 $262 Million
Q3 2018 Nov 14, 2018	BUY	$85.86 - $107.31 $105 Million - $132 Million	1,227,904 Added 50.99%	3,636,222 $390 Million
Q2 2018 Aug 14, 2018	BUY	$75.7 - $86.88 $5.6 Million - $6.43 Million	74,024 Added 3.17%	2,408,318 $206 Million
Q1 2018 May 14, 2018	BUY	$74.21 - $87.6 $90.1 Million - $106 Million	1,214,407 Added 108.44%	2,334,294 $181 Million
Q4 2017 Feb 09, 2018	BUY	$81.94 - $87.89 $61.7 Million - $66.2 Million	752,919 Added 205.17%	1,119,887 $94.6 Million
Q3 2017 Nov 14, 2017	BUY	$77.07 - $85.54 $28.3 Million - $31.4 Million	366,968	366,968 $31.4 Million

Others Institutions Holding LLY

# of Institutions

3,716

Shares Held

738M

Call Options Held

7.09M

Put Options Held

7.24M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $835B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.

Account

Arrowstreet Capital, Limited Partnership Eli Lilly & CO Transaction History